Tech Company Financing Transactions
Ansun BioPharma Funding Round
On 5/15/2018, Ansun BioPharma secured $85 million in Series A funding from Lilly Asia Ventures, SinoPharm Capital and 3E Bioventures.
Transaction Overview
Company Name
Announced On
5/15/2018
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series A
Investors
Lilly Asia Ventures (Lead Investor) (Yi Shi)
SinoPharm Capital (Lead Investor) (Xiaoming Yang)
Proceeds Purpose
Ansun plans to use the proceeds from the Series A to fund a Phase 3 clinical trial of its experimental anti-viral medication, DAS181.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3030 Callan Rd.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nancy Chang
Chief Marketing Officer
Stanley Lewis
Chief Technical Officer
George Wang
VP - Bus. Development
Jennifer Ho
VP - Operations
Mikael Havluciyan
VP - Regulatory Affairs
Connie Lu
Browse more venture capital transactions:
Prev: 5/15/2018: QuickStart venture capital transaction
Next: 5/15/2018: IsoPlexis venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. All VC database entries on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs